SEC Company Response from Grace Therapeutics, Inc. (GRCE) (CIK 0001444192) (GRCE) — Dec 19, 2017
Grace Therapeutics, Inc. (GRCE) (CIK 0001444192)
Date: Dec. 19, 2017 · CIK: 0001444192 · Accession: 0001193125-17-373165
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220755
Letter
The Benchmark Company, LLC
150 E 58th Street, 17th floor
New York, NY 10155
Dawson James Securities, Inc.
1 North Federal Highway, 5th Floor
Boca Raton, FL 33432
December 19, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Acasti Pharma, Inc. (the “Company”)
Registration Statement on Form F-1
File No. 333-220755
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as underwriter of the proposed offering, hereby joins the request of Acasti Pharma, Inc. that the effective date of the above-referenced Registration Statement on Form F-1 be declared effective at 4:30 p.m. (Washington, D.C. time) on Tuesday, December 19, 2017, or as soon as practicable thereafter.
In connection with this acceleration request and pursuant to Rule 460 under the Securities Act, please be advised that between December 15, 2017 and the date hereof, approximately 1,350 copies of the preliminary prospectus dated December 14, 2017 were distributed to underwriters, dealers, institutions and others.
The undersigned advise that the underwriters have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Sincerely,
The Benchmark Company, LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP The Benchmark Company, LLC 150 E 58th Street, 17th floor New York, NY 10155 Dawson James Securities, Inc. 1 North Federal Highway, 5th Floor Boca Raton, FL 33432 December 19, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Acasti Pharma, Inc. (the “Company”) Registration Statement on Form F-1 File No. 333-220755 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as underwriter of the proposed offering, hereby joins the request of Acasti Pharma, Inc. that the effective date of the above-referenced Registration Statement on Form F-1 be declared effective at 4:30 p.m. (Washington, D.C. time) on Tuesday, December 19, 2017, or as soon as practicable thereafter. In connection with this acceleration request and pursuant to Rule 460 under the Securities Act, please be advised that between December 15, 2017 and the date hereof, approximately 1,350 copies of the preliminary prospectus dated December 14, 2017 were distributed to underwriters, dealers, institutions and others. The undersigned advise that the underwriters have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Sincerely, The Benchmark Company, LLC By: /s/ John J. Borer Name: John J. Borer Title: Senior Managing Director Dawson James Securities, Inc. By: /s/ Robert D. Keyser, Jr. Name: Robert D. Keyser, Jr. Title: CEO